Sign in Subscribe
Cancer research

Sunnybrook Health Sciences Centre Launches Clinical Trial to Study New Radiation Therapy Approach for Large Brain Tumors

Strategic Insights

— 1 min read

A new clinical trial at Sunnybrook Health Sciences Centre aims to study the effectiveness of a combined radiation therapy approach for patients with large brain tumors. The trial, which is currently recruiting participants, will investigate the use of the Gamma Knife and a linear accelerator to deliver precise radiation therapy while minimizing damage to healthy brain tissue. The study's investigators believe that this combined approach may improve treatment outcomes for patients with large brain tumors, reducing the risk of side effects and improving tumor control.

Key Takeaways:

  • The trial, titled GK-LIVE, is a Phase 2 clinical trial studying the effectiveness of combined Gamma Knife/Linac hypofractionated stereotactic radiosurgery for large intracranial volumes.
  • The study aims to recruit 60 participants from the USA and will investigate the use of a combined radiation therapy approach for patients with large brain tumors.
  • The current standard treatment for large brain tumors at Sunnybrook involves 5 daily treatments using a linear accelerator, but this approach may not be effective for all patients.
  • The study will compare the outcomes of the combined Gamma Knife/Linac treatment to the standard treatment approach, with a focus on tumor control and side effect reduction.
  • The Gamma Knife is particularly good at delivering precise radiation while sparing nearby healthy tissue, which may improve treatment outcomes.
  • The study will also investigate whether there are unique biological mechanisms between the two technologies that could be leveraged to improve cancer control.
  • The trial is open for recruiting and will provide valuable insights into the effectiveness of the combined treatment approach.

Statistics:

  • The trial aims to recruit 60 participants from the USA.
  • The study will compare the outcomes of the combined Gamma Knife/Linac treatment to the standard treatment approach.
  • The trial is a Phase 2 clinical trial, indicating that it will further investigate the efficacy and feasibility of the combined treatment approach.
  • The study aims to reduce the risk of side effects and improve tumor control for patients with large brain tumors.

Sources:

  • ClinicalTrials.gov
  • Sunnybrook Health Sciences Centre

Read more